Attached files
| file | filename |
|---|---|
| EX-99.5 - EXHIBIT 99.5 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-5.htm |
| EX-99.4 - EXHIBIT 99.4 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-4.htm |
| EX-99.3 - EXHIBIT 99.3 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-3.htm |
| EX-99.2 - EXHIBIT 99.2 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-1.htm |
| 8-K - FORM 8-K - ALBANY MOLECULAR RESEARCH INC | v440429_8k.htm |
Exhibit 99.6
Reconciliation of Lauro 57 Reported EBITDA to Euticals Adjusted EBITDA
(in € thousands)
| 2013 | 2014 | 2015 | ||||||||||
| As Reported EBITDA (IFRS) - Lauro 57 | € | 21,383 | € | 21,627 | € | 29,564 | ||||||
| + Severance Charges | 2,547 | 400 | ||||||||||
| + Consulting & Acquisition Costs | 1,016 | |||||||||||
| + Prior Year Extraordinary Items | 294 | 1,000 | ||||||||||
| + Bank Commissions | 793 | 909 | 692 | |||||||||
| + Change in Environmental Provision | 795 | (543 | ) | |||||||||
| + Provision Allocation | 1,080 | 124 | ||||||||||
| + Provision for Receivables | 2,450 | 192 | ||||||||||
| + R&D Write-off | 1,043 | |||||||||||
| + Non-Cash Employee Benefits Impact | (236 | ) | (141 | ) | ||||||||
| Adjusted EBITDA (IFRS) - Lauro 57 | € | 31,164 | € | 23,567 | € | 30,256 | ||||||
| + Holding Company Costs | 168 | 60 | 220 | |||||||||
| Adjusted EBITDA (IFRS) - Euticals | € | 31,333 | € | 23,627 | € | 30,476 | ||||||
| - Capitalized R&D Costs | (3,072 | ) | (4,957 | ) | (4,664 | ) | ||||||
| - Bank Commissions | (793 | ) | (909 | ) | (692 | ) | ||||||
| Adjusted EBITDA - Euticals | € | 27,467 | € | 17,761 | € | 25,120 | ||||||
| Euro to USD FX Translation Rate | 1.130 | 1.130 | 1.130 | |||||||||
| Adjusted EBITDA - Euticals | $ | 31,038 | $ | 20,070 | $ | 28,386 | ||||||